OBESITY MANAGEMENT - A COMPARATIVE REVIEW OF THE EFFICACY AND SAFETY OF BARIATRIC SURGERY AND TIRZEPATIDE THERAPY
Authors:
- Wojciech GąskaWGWojciech Gąska
- Ignacy RożekIRIgnacy Rożek
- Izabela LekanILIzabela Lekan
- Joanna MazurekJMJoanna Mazurek
- Agnieszka BrzezińskaABAgnieszka Brzezińska
- Weronika TuszyńskaWTWeronika Tuszyńska
- Alicja SodolskaASAlicja Sodolska
- Michał LenartMLMichał Lenart
- Barbara MadońBMBarbara Madoń
- Barbara TeresińskaBTBarbara Teresińska
Open Access
- 22 September 2025
- journal article
- review article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(47))
Abstract
Objective: Obesity is a major global health burden associated with increased morbidity, mortality, and healthcare costs. This review aimed to compare the efficacy and safety of tirzepatide, a novel dual GLP-1/GIP receptor agonist, with bariatric surgery, focusing on their roles in weight reduction, metabolic improvement, and long-term risk–benefit profiles. Methods: A comprehensive literature search was performed using PubMed and official regulatory and professional society sources (FDA, EMA, MHRA, IFSO). Search terms included “obesity,” “bariatric surgery,” “tirzepatide,” and “GLP-1 and GIP receptor agonist.” Only peer-reviewed English-language studies with high levels of evidence, including randomized controlled trials, meta-analyses, systematic reviews, and clinical guidelines, were included. Key Findings: Bariatric surgery, particularly Roux-en-Y gastric bypass and sleeve gastrectomy, was associated with the most profound and durable weight loss (25–28% short-term; 18–25% long-term), alongside significant remission of type 2 diabetes, hypertension, and dyslipidemia. However, its invasive nature and risk of perioperative and late complications necessitate multidisciplinary follow-up. Tirzepatide demonstrated dose-dependent reductions in body weight (~10–20%), improved glycemic control, lipid profiles, and blood pressure, and enhanced quality of life. Its safety profile was favorable, predominantly gastrointestinal, but long-term data remain limited. Conclusions: Bariatric surgery remains the gold standard for severe obesity due to its magnitude and sustainability of benefits. Tirzepatide represents a promising, less-invasive pharmacological option, particularly for patients with moderate obesity or contraindications to surgery. Further research is required to establish its long-term efficacy and safety profile.Keywords
This publication has 24 references indexed in Scilit:
- Tirzepatide for overweight and obesity managementExpert Opinion on Pharmacotherapy, 2024
- Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trialEndocrine, 2024
- IFSO Worldwide Survey 2020–2021: Current Trends for Bariatric and Metabolic ProceduresObesity Surgery, 2024
- Recent advances in bariatric surgery: a narrative review of weight loss proceduresAnnals of Medicine & Surgery, 2023
- Economic impacts of overweight and obesity: current and future estimates for 161 countriesBMJ Global Health, 2022
- As the prevalence of obesity increases, rationing arthritis care is not the answerOsteoarthritis and Cartilage, 2022
- The menace of obesity to depression and anxiety prevalenceTrends in Endocrinology & Metabolism, 2022
- Improvement in mood symptoms after post‐bariatric surgery among people with obesity: A systematic review and meta‐analysisDiabetes/Metabolism Research and Reviews, 2021
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonistJCI Insight, 2020
- Clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery: update 2020 endorsed by IFSO-EC, EASO and ESPCOPSurgical Endoscopy, 2020